[go: up one dir, main page]

DK2276767T3 - Benzopyran- og benzoxepinforbindelser som pi3k-inhibitorer og anvendelsesfremgangsmåder - Google Patents

Benzopyran- og benzoxepinforbindelser som pi3k-inhibitorer og anvendelsesfremgangsmåder

Info

Publication number
DK2276767T3
DK2276767T3 DK09726963.3T DK09726963T DK2276767T3 DK 2276767 T3 DK2276767 T3 DK 2276767T3 DK 09726963 T DK09726963 T DK 09726963T DK 2276767 T3 DK2276767 T3 DK 2276767T3
Authority
DK
Denmark
Prior art keywords
benzopyrane
methods
pi3k inhibitors
benzoxepine
compounds
Prior art date
Application number
DK09726963.3T
Other languages
English (en)
Inventor
Bing-Yan Zhu
Paul Goldsmith
Tracy Bayliss
Adrian FOLKES
Neil Pegg
Steven Do
Richard Goldsmith
Tim Heffron
Aleksandr Kolesnikov
Steven Staben
Alan G Olivero
Michael Siu
Daniel P Sutherlin
Original Assignee
Genentech Inc
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Hoffmann La Roche filed Critical Genentech Inc
Application granted granted Critical
Publication of DK2276767T3 publication Critical patent/DK2276767T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK09726963.3T 2008-03-31 2009-03-30 Benzopyran- og benzoxepinforbindelser som pi3k-inhibitorer og anvendelsesfremgangsmåder DK2276767T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4082708P 2008-03-31 2008-03-31
US10222008P 2008-10-02 2008-10-02
PCT/US2009/038795 WO2009123971A1 (en) 2008-03-31 2009-03-30 Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use

Publications (1)

Publication Number Publication Date
DK2276767T3 true DK2276767T3 (da) 2014-07-14

Family

ID=40790991

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09726963.3T DK2276767T3 (da) 2008-03-31 2009-03-30 Benzopyran- og benzoxepinforbindelser som pi3k-inhibitorer og anvendelsesfremgangsmåder

Country Status (21)

Country Link
US (4) US7928248B2 (da)
EP (1) EP2276767B1 (da)
JP (1) JP5511786B2 (da)
KR (1) KR101626996B1 (da)
CN (1) CN102333779B (da)
AR (1) AR071112A1 (da)
AU (1) AU2009231885B2 (da)
BR (1) BRPI0910346A2 (da)
CA (1) CA2719032C (da)
CL (1) CL2009000780A1 (da)
DK (1) DK2276767T3 (da)
ES (1) ES2480994T3 (da)
IL (1) IL208359A (da)
MX (1) MX2010010659A (da)
PE (1) PE20091720A1 (da)
PL (1) PL2276767T3 (da)
RU (1) RU2506267C2 (da)
SI (1) SI2276767T1 (da)
TW (1) TWI443102B (da)
WO (1) WO2009123971A1 (da)
ZA (1) ZA201007218B (da)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
RU2506267C2 (ru) 2008-03-31 2014-02-10 Дженентек, Инк. Бензопирановые и бензоксепиновые ингибиторы рi3k и их применение
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
KR20120046723A (ko) * 2009-07-02 2012-05-10 노파르티스 아게 Ｐｉ３ｋ 억제제로서 유용한 2-카르복스아미드 시클로아미노 우레아
AU2010299820A1 (en) * 2009-09-28 2012-04-19 F. Hoffmann-La Roche Ag Benzoxepin PI3K inhibitor compounds and methods of use
ES2444779T3 (es) 2009-09-28 2014-02-26 F. Hoffmann-La Roche Ag Compuestos de benzoxazepina inhibidores de la PI3K y su utilización en el tratamiento de cáncer
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
ES2759949T3 (es) * 2009-10-29 2020-05-12 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos
HRP20171537T1 (hr) 2009-11-05 2017-12-15 Rhizen Pharmaceuticals S.A. Novi modulatori benzopiran kinaze
WO2011058149A1 (en) 2009-11-13 2011-05-19 Merck Serono S.A. Tricyclic pyrazol amine derivatives
US9072783B2 (en) 2009-11-18 2015-07-07 Aridis Pharmaceuticals Highly dispersible powders, compositions and methods for preparation
MA34797B1 (fr) 2010-08-11 2014-01-02 Millennium Pharm Inc Hétéroaryles et leurs utilisations
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
JP2013533318A (ja) 2010-08-11 2013-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッド ヘテロアリールおよびその使用
PH12013500723A1 (en) 2010-10-13 2017-08-23 Millennium Pharm Inc Heteroaryls and uses thereof
RU2013143747A (ru) 2011-03-21 2015-04-27 Ф. Хоффманн-Ля Рош Аг Соединения бензоксазепина, селективные в отношении pi3k p110 дельта и способы их применения
KR101992311B1 (ko) 2011-05-04 2019-09-27 리젠 파마슈티컬스 소시에떼 아노님 단백질 키나아제의 조절제로서 신규한 화합물
AU2012262748B2 (en) 2011-05-27 2017-03-02 Lexicon Pharmaceuticals, Inc. 4H-thieno[3,2-c]chromene-based inhibitors of Notum Pectinacetylesterase and methods of their use
AR089999A1 (es) 2012-02-17 2014-10-01 Hoffmann La Roche Compuestos triciclicos y metodos para el uso de los mismos
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20160027218A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
LT2870157T (lt) 2012-07-04 2017-12-11 Rhizen Pharmaceuticals S.A. Selektyvieji pi3k delta inhibitoriai
EP2914260A1 (en) 2012-10-31 2015-09-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
RU2649976C2 (ru) 2013-03-13 2018-04-06 Ф. Хоффманн-Ля Рош Аг Способ получения бензоксазепиновых соединений
MX2015011899A (es) 2013-03-15 2016-05-05 Genentech Inc Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EA201691872A1 (ru) 2014-03-19 2017-04-28 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2014413483B2 (en) 2014-12-11 2019-07-25 Natco Pharma Limited 7-(morpholinyl)-2-(N-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs
MX376112B (es) * 2015-03-30 2025-03-07 Jubilant Biosys Ltd Derivados fusionados tricíclicos de 1-(ciclo)alquil piridin-2-ona como compuestos inhibidores de la familia bet de bromodominios, y el uso de los mismos en el tratamiento de trastornos proliferativos o cáncer.
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2018023017A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of treating prostate cancer
WO2018045149A1 (en) 2016-09-02 2018-03-08 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2019018584A1 (en) 2017-07-18 2019-01-24 GiraFpharma LLC HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
AU2018302178A1 (en) 2017-07-18 2020-02-13 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
US11046646B2 (en) 2017-08-09 2021-06-29 Bristol-Myers Squibb Company Alkylphenyl compounds
WO2019032631A1 (en) 2017-08-09 2019-02-14 Bristol-Myers Squibb Company Oxime ether compounds
CN107805255B (zh) * 2017-09-22 2020-06-16 中国药科大学 呋喃[3，2-b]吡啶-2(1H)-酮类化合物、制备方法和医药用途
AU2019232437A1 (en) 2018-03-07 2020-10-08 Bayer Aktiengesellschaft Identification and use of ERK5 inhibitors
CN110467629B (zh) * 2018-05-09 2022-04-08 上海迪诺医药科技有限公司 苯醌衍生物、其药物组合物及应用
US11254670B2 (en) 2019-01-18 2022-02-22 Nuvation Bio Inc. 1,8-naphthyridinone compounds and uses thereof
KR20210116550A (ko) 2019-01-18 2021-09-27 누베이션 바이오 인크. 아데노신 길항제로서의 헤테로시클릭 화합물
CN114156414B (zh) * 2021-11-30 2024-05-31 合肥工业大学 一种高效稳定CsPbI3无机钙钛矿电池的制备方法
CN117209457B (zh) * 2022-06-09 2025-08-15 四川师范大学 一种α-手性脒化合物的合成
CN115403591A (zh) * 2022-10-08 2022-11-29 河南师范大学 一种合成萘并噻吩并奥塞平并异喹啉酮类化合物的方法
WO2025082467A1 (zh) * 2023-10-19 2025-04-24 成都先导药物开发股份有限公司 一种免疫调节剂

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8504702D0 (en) * 1985-02-23 1985-03-27 Zyma Sa Tricyclic compounds
FR2677356B1 (fr) * 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
US5612356A (en) * 1992-12-28 1997-03-18 Eisai Co., Ltd. Heterocycle-containing carbonic acid derivatives
US5985799A (en) * 1995-11-17 1999-11-16 E.I. Du Pont De Nemours And Company Tricyclic herbicidal heterocycles
DE19831878C2 (de) * 1998-07-17 2001-05-17 Aventis Pharma Gmbh Polycyclische Thiazolidin-2-yliden Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE19908538A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908533A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908537A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
DE19908535A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US7273880B2 (en) * 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
AU2001246494A1 (en) 2000-03-03 2001-09-12 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
US20040198791A1 (en) * 2001-06-05 2004-10-07 Yoshinari Sato Fused imidazole derivative
JP2005536518A (ja) * 2002-07-19 2005-12-02 ファルマシア コーポレイション 炎症治療のための置換チオフェンカルボキサミド化合物
WO2004069245A1 (en) * 2003-02-07 2004-08-19 Warner-Lambert Company Llc Oxazolidinone derivates n-substituted by a tricyclic ring, for use as antibacterial agents
AU2005293607A1 (en) * 2004-10-07 2006-04-20 Boehringer Ingelheim International Gmbh PI3 kinases
CN101039667A (zh) * 2004-10-15 2007-09-19 辉瑞大药厂 双相性精神障碍和相关症状的治疗
RU2281947C1 (ru) * 2005-07-05 2006-08-20 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Аннелированные карбамоилазагетероциклы, фокусированная библиотека, фармацевтическая композиция и способ получения
CA2659956C (en) * 2006-08-04 2016-01-05 Lewis C. Cantley Inhibitors of pyruvate kinase and methods of treating disease
US8779154B2 (en) * 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
RU2506267C2 (ru) 2008-03-31 2014-02-10 Дженентек, Инк. Бензопирановые и бензоксепиновые ингибиторы рi3k и их применение

Also Published As

Publication number Publication date
US20090247567A1 (en) 2009-10-01
AU2009231885A1 (en) 2009-10-08
CN102333779B (zh) 2015-12-09
JP2011517457A (ja) 2011-06-09
US8399690B2 (en) 2013-03-19
MX2010010659A (es) 2010-10-26
KR101626996B1 (ko) 2016-06-02
CN102333779A (zh) 2012-01-25
WO2009123971A1 (en) 2009-10-08
ZA201007218B (en) 2012-06-27
AR071112A1 (es) 2010-05-26
AU2009231885B2 (en) 2014-04-03
RU2506267C2 (ru) 2014-02-10
EP2276767B1 (en) 2014-05-07
BRPI0910346A2 (pt) 2015-10-06
JP5511786B2 (ja) 2014-06-04
SI2276767T1 (sl) 2014-08-29
US20140336154A1 (en) 2014-11-13
US9309265B2 (en) 2016-04-12
US20130123263A1 (en) 2013-05-16
IL208359A0 (en) 2010-12-30
HK1147741A1 (en) 2011-08-19
TWI443102B (zh) 2014-07-01
KR20100137551A (ko) 2010-12-30
US8846762B2 (en) 2014-09-30
RU2010143319A (ru) 2012-05-10
US7928248B2 (en) 2011-04-19
CL2009000780A1 (es) 2010-01-15
PL2276767T3 (pl) 2014-09-30
TW200944531A (en) 2009-11-01
IL208359A (en) 2016-07-31
CA2719032A1 (en) 2009-10-08
PE20091720A1 (es) 2009-11-26
US20110130363A1 (en) 2011-06-02
EP2276767A1 (en) 2011-01-26
ES2480994T3 (es) 2014-07-29
CA2719032C (en) 2016-11-08

Similar Documents

Publication Publication Date Title
DK2276767T3 (da) Benzopyran- og benzoxepinforbindelser som pi3k-inhibitorer og anvendelsesfremgangsmåder
CY2020024I2 (el) Αναστολεiς βητα-λακταμασων
IL218800A0 (en) Benzoxepin pi3k inhibitor compounds and methods of use
HRP20150003T1 (xx) Sastavi inhibitora dpp-iv
DK2318389T3 (da) Pyridazinderivater som SMO-inhibitorer
DK2470526T3 (da) Forbindelser og sammensætninger som proteinkinase-inhibitorer
TWI365185B (en) Amidophenoxyindazoles useful as inhibitors of c-met
EP2272817A4 (en) PAI-1 INHIBITORS
ZA201007524B (en) Purine pi3k inhibitor compounds and methods of use
CY2014011I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DK2406253T3 (da) Benzofuranylderivater anvendt som glucokinase-inhibitorer
BRPI0915231A2 (pt) compostos inibidores de quinase e métodos de uso
DK2315756T3 (da) 1,2,5-oxadiazoler som inhibitorer af indolamin-2,3-dioxygenase
DK2086939T3 (da) Pyridiacarboxamid som II-beta-HSDI-inhibitorer
CR10369A (es) Pyrimidine derivatives as pi3k inhibitors
DK2099447T3 (da) Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer
DK2331547T3 (da) Pyrrolopyrimidinforbindelser som CDK-inhibitorer
PT2397142T (pt) Utilizações de inibidores da dpp iv
DK2383271T3 (da) Aminoquinoloner som GSK-3-inhibitorer
DK2220070T3 (da) 2-benzylpyridazinonderivater som Met-kinaseinhibitorer
IL201367A0 (en) 2 - morpholin - 4 - yl - pyrimidines as pi3k inhibitors
DK2513105T3 (da) 2-arylimidazolderivater som pde10a-enzyminhibitorer
EP2239261A4 (en) PYRROLOPYRIMIDINE DERIVATIVE FOR USE AS A PI3K INHIBITOR AND USE THEREOF
BRPI0918564A2 (pt) inibidores
GB0820856D0 (en) Novel inhibitors of flavivirus replication